ATF-ZnPc competed with ATF for uPAR binding, with an IC50 = 8.6 nM and enhanced the antitumor specificity and efficacy of ZnPc in vitro and in vivo on different cancer cell-types [169]. The gene discussed is PLAU; the disease is cancer.